
What We’re Reading: Tirzepatide Outperforms Semaglutide; STDs Continue to Rise Among Older Adults; Nearly Half of US Counties Lack Cardiologist
More patients achieve significant weight loss with tirzepatide; new data show significant increases in sexually transmitted disease (STD) diagnoses; many individuals in cardiology deserts are left at higher risk of dying from heart disease.
Tirzepatide Surpasses Semaglutide in Weight Loss, Diabetes Management
A recent study analyzed more than 18,000 adults who were overweight or had obesity and found that tirzepatide users experienced more significant weight loss than those taking semaglutide,
STD Diagnoses Continue to Surge Among Older Adults
Recent data reveal a 4.8% rise in sexually transmitted disease (STD) diagnoses from 2020 to 2023, with those 65 years and older experiencing a 23.8% increase,
Millions of Individuals Live in Cardiology Deserts
A new study reveals that 46.3% of US counties lack a practicing cardiologist, with most of these counties being rural and having higher rates of cardiovascular risk factors,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.